Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342302 | 0.98 | SMN1; SMN2 (0.38) | SMN1; SMN2ATMTDP1TSHRALDH1A1 | |
| SCHEMBL15541721 | 0.98 | SMN1; SMN2 (0.38) | SMN1; SMN2ATMTDP1TSHRALDH1A1 | |
| SCHEMBL2420027 | 0.90 | — | — | |
| Piperazine SCHEMBL28078125 | 0.88 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHRALDH1A1HSD17B10KDM4E | |
| SCHEMBL9957528 | 0.82 | HTT (0.40) | ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL9957046 | 0.82 | POLB (0.38) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12156734 | 0.81 | HRH3 (0.41) | SMN1; SMN2TSHRALDH1A1KDM4E | |
| SCHEMBL19971101 | 0.80 | SIGMAR1 (0.39) | SMN1; SMN2ALDH1A1SIGMAR1 | |
| SCHEMBL20531089 | 0.80 | GAA (0.35) | ALDH1A1 | |
| SCHEMBL342075 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2TSHRALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651876-B1 | POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECH AG (CH) | 2017-08-09 | — | — | EP | claimed |
| CN-103261146-B | Polyamines having secondary aliphatic amino groups | SIKA TECHNOLOGY AG (CH) | 2016-01-27 | — | — | CN | claimed |
| US-8877955-B2 | Secondary aminosilanes | SIKA TECHNOLOGY AG (CH) | 2014-11-04 | — | — | US | claimed |
| US-20130281562-A1 | SECONDARY AMINOSILANES | SIKA TECHNOLOGY AG (CH) | 2013-10-24 | — | — | US | claimed |
| EP-2651876-A1 | POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | Sika Technology AG (CH) | 2013-10-23 | — | — | EP | claimed |
| EP-2651956-A1 | SECONDARY AMINOSILANES | Sika Technology AG (CH) | 2013-10-23 | — | — | EP | claimed |
| US-20130261270-A1 | POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECHNOLOGY AG (CH) | 2013-10-03 | — | — | US | claimed |
| CN-103313995-A | Secondary aminosilanes | SIKA TECHNOLOGY AG | 2013-09-18 | — | — | CN | claimed |
| CN-103261146-A | Polyamines having secondary aliphatic amino groups | SIKA TECHNOLOGY AG | 2013-08-21 | — | — | CN | claimed |
| EP-2468759-A1 | Secondary Aminosilanes | Sika Technology AG (CH) | 2012-06-27 | — | — | EP | claimed |
| WO-2012080266-A1 | SECONDARY AMINOSILANES | SIKA TECHNOLOGY AG (CH) | 2012-06-21 | — | — | WO | claimed |
| WO-2012080265-A1 | POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECHNOLOGY AG (CH) | 2012-06-21 | — | — | WO | claimed |
| EP-2465843-A1 | Polyamines with secondary aliphatic amines | Sika Technology AG (CH) | 2012-06-20 | — | — | EP | claimed |
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2023196527-A2 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2009010522-A1 | ALDIMINES AND COMPOSITIONS COMPRISING ALDAMINE | SIKA TECHNOLOGY AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-2017260-A1 | Aldimines and compounds containing aldimine | Sika Technology AG (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281562-A1 | SECONDARY AMINOSILANES | AS3MT, SRM, MSN | SMN1; SMN2 542/4885ATM 130/4885TDP1 2124/4885 |
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | SMN1; SMN2 3496/4885ATM 556/4885TDP1 673/4885 |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | PHOSPHO1, SGMS1, PLIN3 | SMN1; SMN2 3781/4885ATM 4020/4885TDP1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.